{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T14:23:36Z","timestamp":1772029416758,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T00:00:00Z","timestamp":1547510400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union Seventh Framework Program","award":["602962"],"award-info":[{"award-number":["602962"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13063-018-3169-3","type":"journal-article","created":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T13:02:52Z","timestamp":1547557372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Gabapentin as add-on to morphine for severe neuropathic or mixed pain in children from age 3\u2009months to 18\u2009years - evaluation of the safety, pharmacokinetics, and efficacy of a new gabapentin liquid formulation: study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"20","author":[{"name":"on behalf of the GAPP consortium","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9516-3088","authenticated-orcid":false,"given":"Thomas G.","family":"de Leeuw","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Mangiarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Lundin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florentia","family":"Kaguelidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tjitske","family":"van der Zanden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar Della","family":"Pasqua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dick","family":"Tibboel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Ceci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia N.","family":"de Wildt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,15]]},"reference":[{"key":"3169_CR1","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1016\/j.pain.2011.07.016","volume":"152","author":"S King","year":"2011","unstructured":"King S, Chambers CT, Huguet A, et al. The epidemiology of chronic pain in children and adolescents revisited: a systematic review. Pain. 2011;152:2729\u201338.","journal-title":"Pain"},{"key":"3169_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0304-3959(00)00269-4","volume":"87","author":"CW Perquin","year":"2000","unstructured":"Perquin CW, Hazebroek-Kampschreur AA, Hunfeld JA, et al. Pain in children and adolescents: a common experience. Pain. 2000;87:51\u20138.","journal-title":"Pain"},{"key":"3169_CR3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3410\/M2-52","volume":"2","author":"NB Finnerup","year":"2010","unstructured":"Finnerup NB, Sindrup SH, Jensen TS. Recent advances in pharmacological treatment of neuropathic pain. F1000 Med Rep. 2010;2:52.","journal-title":"F1000 Med Rep"},{"key":"3169_CR4","doi-asserted-by":"crossref","unstructured":"Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2006;(3):CD006146.","DOI":"10.1002\/14651858.CD006146"},{"key":"3169_CR5","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.4065\/mcp.2009.0649","volume":"85(3 Suppl)","author":"RH Dworkin","year":"2010","unstructured":"Dworkin RH, O\u2019Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(3 Suppl):S3\u201314.","journal-title":"Mayo Clin Proc"},{"key":"3169_CR6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1136\/archdischild-2013-304208","volume":"99","author":"RF Howard","year":"2014","unstructured":"Howard RF, Wiener S, Walker SM. Neuropathic pain in children. Arch Dis Child. 2014;99:84\u20139.","journal-title":"Arch Dis Child"},{"key":"3169_CR7","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.4065\/mcp.2009.0647","volume":"85(3 Suppl)","author":"GA Walco","year":"2010","unstructured":"Walco GA, Dworkin RH, Krane EJ, et al. Neuropathic pain in children: special considerations. Mayo Clin Proc. 2010;85(3 Suppl):S33\u201341.","journal-title":"Mayo Clin Proc"},{"issue":"3 Suppl","key":"3169_CR8","doi-asserted-by":"crossref","first-page":"ES93","DOI":"10.36076\/ppj.2012\/15\/ES93","volume":"15","author":"HS Smith","year":"2012","unstructured":"Smith HS. Opioids and neuropathic pain. Pain Physician. 2012;15(3 Suppl):ES93\u2013110.","journal-title":"Pain Physician"},{"key":"3169_CR9","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1213\/00000539-199812000-00027","volume":"87","author":"S Abdi","year":"1998","unstructured":"Abdi S, Lee DH, Chung JM. The anti-allodynic effects of amitriptyline, gabapentin, and lidocaine in a rat model of neuropathic pain. Anesth Analg. 1998;87:1360\u20136.","journal-title":"Anesth Analg"},{"key":"3169_CR10","first-page":"1026","volume":"288","author":"HL Pan","year":"1999","unstructured":"Pan HL, Eisenach JC, Chen SR. Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats. J Pharmacol Exp Ther. 1999;288:1026\u201330.","journal-title":"J Pharmacol Exp Ther"},{"key":"3169_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0304-3940(00)00769-2","volume":"280","author":"DJ Dooley","year":"2000","unstructured":"Dooley DJ, Mieske CA, Borosky SA. Inhibition of K+-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett. 2000;280:107\u201310.","journal-title":"Neurosci Lett"},{"key":"3169_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0028-3908(01)00172-1","volume":"42","author":"K Fink","year":"2002","unstructured":"Fink K, Dooley DJ, Meder WP, et al. Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology. 2002;42:229\u201336.","journal-title":"Neuropharmacology"},{"key":"3169_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.pain.2008.11.019","volume":"142","author":"CP Taylor","year":"2009","unstructured":"Taylor CP. Mechanisms of analgesia by gabapentin and pregabalin \u2013 calcium channel \u03b12-\u03b4 [Cav\u03b12-\u03b4] ligands. Pain. 2009;142:13\u20136.","journal-title":"Pain"},{"key":"3169_CR14","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1001\/jama.280.21.1837","volume":"280","author":"M Rowbotham","year":"1998","unstructured":"Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280:1837\u201342.","journal-title":"JAMA"},{"key":"3169_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0304-3959(01)00407-9","volume":"94","author":"AS Rice","year":"2001","unstructured":"Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain. 2001;94:215\u201324.","journal-title":"Pain"},{"key":"3169_CR16","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1001\/jama.280.21.1831","volume":"280","author":"M Backonja","year":"1998","unstructured":"Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280:1831\u20136.","journal-title":"JAMA"},{"key":"3169_CR17","first-page":"481","volume":"27","author":"M Bone","year":"2002","unstructured":"Bone M, Critchley P, Buggy DJ. Gabapentin in postamputation phantom limb pain: a randomized, double-blind, placebo-controlled, cross-over study. Reg Anesth Pain Med. 2002;27:481\u20136.","journal-title":"Reg Anesth Pain Med"},{"key":"3169_CR18","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/01.BRS.0000112068.16108.3A","volume":"29","author":"F Levendoglu","year":"2004","unstructured":"Levendoglu F, Ogun CO, Ozerbil O, et al. Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. Spine. 2004;29:743\u201351.","journal-title":"Spine"},{"key":"3169_CR19","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pain.2007.12.011","volume":"138","author":"TE Gordh","year":"2008","unstructured":"Gordh TE, Stubhaug A, Jensen TS, et al. Gabapentin in traumatic nerve injury pain: a randomized, double-blind, placebo-controlled, cross-over, multi-center study. Pain. 2008;138:255\u201366.","journal-title":"Pain"},{"key":"3169_CR20","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1002\/cncr.23008","volume":"110","author":"RD Rao","year":"2007","unstructured":"Rao RD, Michalak JC, Sloan JA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007;110:2110\u20138.","journal-title":"Cancer"},{"key":"3169_CR21","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1177\/135245859700300407","volume":"3","author":"MK Houtchens","year":"1997","unstructured":"Houtchens MK, Richert JR, Sami A, et al. Open label gabapentin treatment for pain in multiple sclerosis. Mult Scler. 1997;3:250\u20133.","journal-title":"Mult Scler"},{"key":"3169_CR22","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1212\/WNL.51.2.609","volume":"51","author":"C Solaro","year":"1998","unstructured":"Solaro C, Lunardi GL, Capello E, et al. An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. Neurology. 1998;51:609\u201311.","journal-title":"Neurology"},{"key":"3169_CR23","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1213\/00000539-200009000-00034","volume":"91","author":"J Mao","year":"2000","unstructured":"Mao J, Chen LL. Gabapentin in pain management. Anesth Analg. 2000;91:680\u20137.","journal-title":"Anesth Analg"},{"key":"3169_CR24","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/00002508-199812000-00014","volume":"14","author":"T McGraw","year":"1998","unstructured":"McGraw T, Stacey BR. Gabapentin for treatment of neuropathic pain in a 12-year-old girl. Clin J Pain. 1998;14:354\u20136.","journal-title":"Clin J Pain"},{"key":"3169_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S0885-3924(00)00243-8","volume":"21","author":"LM Rusy","year":"2001","unstructured":"Rusy LM, Troshynski TJ, Weisman SJ. Gabapentin in phantom limb pain management in children and young adults: report of seven cases. J Pain Symptom Manag. 2001;21:78\u201382.","journal-title":"J Pain Symptom Manag"},{"key":"3169_CR26","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1213\/ANE.0b013e3181d41dc2","volume":"110","author":"LM Rusy","year":"2010","unstructured":"Rusy LM, Hainsworth KR, Nelson TJ, et al. Gabapentin use in pediatric spinal fusion patients: a randomized, double-blind, controlled trial. Anesth Analg. 2010;110:1393\u20138.","journal-title":"Anesth Analg"},{"key":"3169_CR27","unstructured":"GAPP: Gabapentin in Paediatric Pain. https:\/\/www.pediatricpain.eu \/. Accessed 18 February 2018."},{"key":"3169_CR28","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1212\/01.wnl.0000282763.29778.59","volume":"70","author":"RD Treede","year":"2008","unstructured":"Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630\u20135.","journal-title":"Neurology"},{"key":"3169_CR29","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.pain.2010.04.030","volume":"150","author":"RN Harden","year":"2010","unstructured":"Harden RN, Bruehl S, Perez RS, et al. Validation of proposed diagnostic criteria (the \u201cBudapest Criteria\u201d) for complex regional pain syndrome. Pain. 2010;150:268\u201374.","journal-title":"Pain"},{"key":"3169_CR30","volume-title":"WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses","author":"World Health Organization (WHO)","year":"2012","unstructured":"World Health Organization (WHO). WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses. Geneva: WHO; 2012."},{"key":"3169_CR31","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa042580","volume":"352","author":"I Gilron","year":"2005","unstructured":"Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352:1324\u201334.","journal-title":"N Engl J Med"},{"key":"3169_CR32","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"NB Finnerup","year":"2015","unstructured":"Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162\u201373.","journal-title":"Lancet Neurol"},{"key":"3169_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2217\/pmt.15.53","volume":"6","author":"NB Finnerup","year":"2016","unstructured":"Finnerup NB, Attal N. Pharmacotherapy of neuropathic pain: time to rewrite the rulebook? Pain Manag. 2016;6:1\u20133.","journal-title":"Pain Manag"},{"key":"3169_CR34","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.pain.2010.06.019","volume":"150","author":"NB Finnerup","year":"2010","unstructured":"Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150:573\u201381.","journal-title":"Pain"},{"key":"3169_CR35","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1177\/00912700122010384","volume":"41","author":"GM Haig","year":"2001","unstructured":"Haig GM, Bockbrader HN, Wesche DL, et al. Single-dose gabapentin pharmacokinetics and safety in healthy infants and children. J Clin Pharmacol. 2001;41:507\u201314.","journal-title":"J Clin Pharmacol"},{"key":"3169_CR36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0920-1211(01)00311-4","volume":"47","author":"D Ouellet","year":"2001","unstructured":"Ouellet D, Bockbrader HN, Wesche DL, et al. Population pharmacokinetics of gabapentin in infants and children. Epilepsy Res. 2001;47:229\u201341.","journal-title":"Epilepsy Res"},{"key":"3169_CR37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/0091270012439209","volume":"53","author":"R Lal","year":"2013","unstructured":"Lal R, Sukbuntherng J, Luo W, et al. Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil. J Clin Pharmacol. 2013;53:29\u201340.","journal-title":"J Clin Pharmacol"}],"updated-by":[{"DOI":"10.1186\/s13063-019-3519-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000}}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-3169-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-018-3169-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-3169-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T08:14:25Z","timestamp":1662797665000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-018-3169-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,15]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3169"],"URL":"https:\/\/doi.org\/10.1186\/s13063-018-3169-3","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13063-019-3519-9","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,15]]},"assertion":[{"value":"23 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Following publication of the original article [1], we have been notified that the tagging of one of the author names was done incorrectly in the XML version of the paper. Original and corrected tagging can be seen below.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was obtained from the Medical Ethical Committee of the Erasmus Medical Centre, Rotterdam, The Netherlands. Medical ethical review is under way in the other participating centers (EudractCT, 2014-004897-40), and registered at ClinicalTrials.gov (NCT03275012).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Full consent for publication was given by the GAPP consortium.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"49"}}